![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 05, 2013 7:59:06 AM
I can now confirm (people can question, but that is not my problem) that LymPro analytical performance in BD lab has returned stupendous numbers. The 96/98 % specificity/sensitivity has been replicated, confirming AMBS's previous study with 160 patient population.The focus has now shifted to who AMBS selects to carry out the CLIA work which should bring some decent funding to AMBS.
By the way, the recent run from 0.03 to 0.09 was not a fluke. Gerald was invited all the way to Helsinki not to just sit on a Alz discussion for 1 hour. Yesterday's little 30% stunt was staged by crooks. It is a shame such things are allowed by SEC. Watch out for some real fun, real soon. It is time to be pleasantly surprised.
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM